Dipharma S.A. is a Swiss pharmaceutical company specialized in developing high quality, improved medicines for rare diseases.  Dipharma S.A. is part of a third generation group of family companies grown to a global presence.

With a portfolio of products for the treatment of Phenylketonuria, Gaucher Disease, Niemann Pick Type C, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma SA works every day to provide improved solutions for people affected by inborn metabolic diseases at an affordable cost and with a global reach.



  • 1897

    Birth of Mario Biazzi (1897-1974)
    Chemical engineer, founder of Dipharma

  • 1949

    Incorporation of Dinamite S.p.A. for manufactuning of civil explosives in Mereto, Italy

  • 1960s

    First production of an Active Pharmaceutical Ingredient: nitroglycerin for pharmaceutical use.

  • 1970

    First inspection by the US FDA: Dipharma becomes a global player in the API industry.

  • 2014

    Incorporation of Dipharma SA in Chiasso, Switzerland.

  • 2015

    Our first medicine (Diterin®) receives the first marketing authorization.

  • 2016

    First product (Miglustat) filed to US FDA.

    First patients treated with Diterin® (Sapropterin dihydrochloride).

Our Vision:
Being recognized as a reference company offering superior value to people affected by inborn metabolic diseases

Our Mission:
We offer improved therapeutic solutions to patients, physicians and payers, and strive to become the preferred specialty pharma provider in Europe and through a network of partners sharing our vision in markets outside of Europe

Dipharma SA is focused at improving quality of treatments and compliance for the patient, thus improving patients’ quality of life. Our team is committed both to providing improved generic medicines to patients in need, and to developing completely new investigational treatments. The strength and the fast growth of our patent portfolio witness how seriously we deal with innovation. This is how we build our road to the future, for life.


People are the core value of Dipharma. Sharing enthusiasm, competencies and knowledge is the secret behind our teams’ individual and collective growth.

Board of Directors

  • Barbara Geinoz-Biazzi


    Barbara Geinoz-Biazzi is a Physician who in parallel has worked in hospitals, private practice and schools. She is the president of Biazzi S.A., an engineering company making projects and plants for the chemical industry, which was incorporated by her father more than 80 years ago. She is married and has three children and four grandchildren.

  • Giorgio Mosconi

    Non-executive Director

    Giorgio Mosconi joined Dipharma SA Board in 2016. Giorgio has more than 25 years’ experience in the pharmaceutical industry in many senior positions, the last one being senior vice president and scientific director in Gentium GmbH (currently owned by Jazz).

  • Marc-Olivier Geinoz

    Chief Executive Officer

    Marc-Olivier Geinoz, is the founder of Dipharma SA. Since 2005, he is also managing director of Dipharma Francis Srl, an API manufacturer with sales of circa $125M in over 50 countries. Prior to that, he held senior roles with companies belonging to the Schindler Group and was founder of an IT services company. He holds a M.B.A., is married and has two children.



Management team

  • Marc-Olivier Geinoz

    Chief Executive Officer

    Marc-Olivier Geinoz, is the founder of Dipharma SA. Since 2005, he is also managing director of Dipharma Francis Srl, an API manufacturer with sales of circa $125M in over 50 countries. Prior to that, he held senior roles with companies belonging to the Schindler Group and was founder of an IT services company. He holds a M.B.A., is married and has two children.



  • Mithu Sen

    Chief Business Development Officer

    Senior industry executive with a successful track record of corporate and business development. He combines his knowledge of pharmacology, regulatory affairs, quality and communication in managing Dipharma portfolio. His key strengths are in relationship management, strategic analysis of data and risk mitigation. Mithu holds a Ph.D. and coveted credentials from TOPRA and RQA. He has worked in various parts of the world with Procter & Gamble, Sigma-Tau, DSM etc.


  • Paola Tocchetti

    Chief Operation Officer

    Graduated at University of Milan in Biological Sciences. She has more than 25 years of experience in the Pharmaceutical field. In one of her recent position, she was leading a team that has successfully obtained marketing authorizations for a biotech medicinal product in an orphan indication worldwide.

  • Andreas Diedenhofen
    Chief Medical & Market Access Officer
    Andreas is a physician by training and holds an EMBA from the Polytechnic of Milan. He has thirty years of industry experience holding senior commercial and medical positions both in “Big Pharma” as well as in privately owned companies. Andreas covered global, regional and national roles and has an extensive orphan drug development and launch experience.

Dipharma Team

  • Gilles Pain
    IP Manager

    Gilles holds a PhD in Organic Chemistry from the University of Châtenay-Malabry. Gilles has worked as Medicinal Chemistry Group Leader in pharmaceutical research companies in Italy and UK. Prior to joining Dipharma, he built a solid experience as patent counsel with Sigma-Tau for 7 years.

  • Fabio Cannata

    Business Development Director

    Since 2012, he has been BD and investor relations manager in a publicly-traded startup biotechnology company, managing the development of oncology products and gene therapies for rare diseases. Prior to that, he held different roles as a scientist, and as a strategic consultant for an internationally-known consulting firm.

  • Silvia Armaroli

    Senior Project Manager

    Silvia holds a Degree in Organic Chemistry from the Alma Mater University in Bologna, and post graduate diplomas in Drug Design and Synthesis, as well as in Formulation, Pharmaceutical development and Drug control. Prior to joining Dipharma, she was working for 10 years with Sigma-Tau.

  • Silvestro Nasturzio

    Legal Manager

    Silvestro graduated in law (J.D.) and holds a LL.M. degree. Before joining Dipharma, he practiced law for more than 7 years at two well-known independent law firms, respectively based in Milan and New York, as well as at the corporate department of a UK magic circle law firm based in Milan.

  • Marco Sartori

    Finance and Administration 

    Graduated in economics at the Insubria University (Varese). Before joining Dipharma he worked as accountant for 5 years in an international company in Switzerland. Besides the accounting skills, he built a wide experience on international trading activities and logistics.

  • Valentina Vajani
    Quality Assurance Manager

    Graduated at University of Milan in Industrial Biotechnology, she has a 10-year experience in the field of both generics and brand-name finished drugs. Valentina works with other staff to establish procedures and quality standards and to monitor these against agreed targets. She is responsible for maintaining the Company Quality System in compliance with GMP and GDP.

  • Angela Tanieli Ottavi

    Assistant to the CEO

    Before joining Dipharma, Angela worked for more than 20 years in the Swiss banking sector in Zurich and Ticino. She has covered roles of growing responsibilities up to Investment Manager and Deputy Director. She has a proven track record of deliverable in finance and asset management.
  • Paolo Fratelli
    Regulatory Affairs Manager
    Paolo Fratelli holds a degree in Chemistry from University of Pavia and a Master in General Management from the University of Insubria.
    Before joining Dipharma SA, Paolo has worked in the CMC/Regulatory Affairs department in Pfizer Italia and in the Regulatory Affairs Department of Ginsana SA.
  • Daniele Sterrantino
    Regulatory Affairs Manager
    Daniele holds a Degree in Pharmaceutical Chemistry and Technology from the University of Catania. Before joining Dipharma, he worked for 10 years in Regulatory Affairs in Italian affiliates and manufacturing sites of multinational pharma companies, as well as, pharma firms based in Ticino, Switzerland.
  • Concetta Zocco
    Regulatory Affairs Associate
    Concetta graduated in Biological Sciences prior to completing a two-year Master’s degree in Regulatory Affairs at the Pavia University. She has been working in several pharmaceutical companies, involved in the preparation of dossiers for marketing authorization and life cycle management for Europe and for foreign markets, mainly in the orphan drugs field.

Medical advisors

  • Dr. Paul Giessen

    He Has been an honorary Consultant in Pediatric Metabolic Diseases at Great Ormond Street Hospital for Children and Wellcome Trust Senior Research Fellow in Clinical Sciences at the UCL Great Ormond Street Institute of Child Health (UK) since March 2011. He specialises in pediatric inherited metabolic disorders.



In September 2015 we opened our new offices in Chiasso, Switzerland. We put a lot of efforts and thoughts in order to create the best location for our employees. Our primary goal is to enhance our staff’s performance, as they are the engine that make our company grow, adapt, improve and innovate.
Our open-floor offices have been designed to promote collaboration and teamwork and our internal bar, located in the heart of the company, is there to celebrate our successes.

The Grit:
– Always act as if success or failure is within your control
– Put aside things you have no ability to impact
– See the past as valuable training and nothing more
– Focus only on impressing yourself
– Celebrate the success of others
– Never allow yourself to whine, complain, or criticise
– Count your blessings